Dr Edward Watson
CEO, Middlemore Clinical Trials, Auckland, NZ
Edward is a qualified physician. He joined the pharmaceutical industry as a Medical Director for organisations across New Zealand and Australia. Prior to becoming Chief Execuitve Officer for Middlemore Clinical Trials Edward had his own clinical research unit and led the establishment of the Auckland Cancer Trials Centre, focusing on early phase oncology trials at Auckland Hospital. Edward’s commercial experience includes a range of senior management positions in several US based pharmaceutical companies, such as MSD, Schering Plough and Pfizer. Edward’s clinical trial experience extends from being the Principal Investigator for Phase I to Phase IV in multiple therapeutic areas and ha member of safety boards (DSMB) for several multinational trials in the Asia pacific region.
Trends in Research Sites
The conduct of clinical trials at a research site level is undergoing a significant transformation. Forces driving this change include the poor performance and economic limitations of traditional investigative sites, the complexity of modern trials and the pressure to integrate clinical research into patients’ clinical care. The high turnover of Principal investigators, the majority of whom are involved in only on study protocol, means that no iterative learning is occurring leading to less effective and efficient recruitment.
Clinical research sites that can adapt to this changing landscape will grow and flourish. Adaption involves acknowledgement of current weaknesses in site operations and the development of the next generation of Principal investigators. Importantly it is also understanding the new ways to engage with potential participants and to show them the benefits of being involved in a clinical trial. For sponsors of clinical trials there is the need to generate more data in a more timely and efficient manner
Patients tend to have better outcomes when participating in clinical trials than when receiving standard of care. Thus there is the desire from patients to have clinical trials as an option in the paradigm of their care.